The global particle therapy market is experiencing growth and is projected to reach USD 1,634.4 million by 2030. This development can be attributed to the high acceptance of particle treatment for cancer treatment armed with the rise in the count of particle therapy centers throughout the globe.
In recent years, proton therapy dominated the industry with a revenue share of above 90%, and the category is also estimated to experience a higher CAGR, of around 8.5%, in the projection period. This development can be credited to the high acceptance of this treatment for treating numerous cancers, like brain tumors, pediatric cancer, and breast cancer.
According to a government agency, above 2 million females were identified with breast cancer in 2020 throughout the globe, making it the most prevalent cancer. Products, like synchrotrons, cyclotrons, and synchrocyclotrons, hold over 80% of the industry share, credited to the increasing acceptance of cyclotrons in numerous hospitals armed with numerous benefits provided by them like low prices. Furthermore, the increasing shift toward nuclear scans for analysis, and the accessibility of technically progressive diagnostic devices also propel the industry development in this category.
Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=particle-therapy-market
During the projection period, the single-room systems category is projected to experience a higher CAGR, of approximately 9%, because of the low price per treatment and lower development price of a single-room facility. For example, according to a government source, the price of a single-room facility is approximately USD 30 million, which is relatively very high in the case of a multi-room capacity that can price approximately USD 100 million.
In recent years, pediatric cancer accounted for over 25% of the particle therapy market share, and the category is estimated to witness the fastest development, growing at a CAGR of approximately 9.0%, in the projection period, credited to its high occurrence throughout the world. Particle treatment is typically utilized in the treatment of pediatric patients because of the high mitosis rate in kids, which needs treatment that straight targets the tumor with very less long-term side effects. It offers high accuracy and radiation control with nearly no exposure to normal body cells.
In recent years, the European particle therapy industry generated the highest revenue share. Moreover, the regional industry is projected to witness the highest CAGR, of approximately 9%, in the projection period, because of the increasing count of particle therapy amenities offering clinical processes in the region. For example, above 50% of the particle therapy centers exist in Europe.
This is due to the supportive government guidelines and the existence of technologically progressive solutions for illness diagnosis. Furthermore, the existence of a huge count of distribution platforms also boosts the industry development in the region.